Alkermes and Janssen enter arbitration over nanocrystal tech
21-04-2022
PTAB institutes IPR of Nalox-1 opioid overdose treatment
29-08-2019
Biopharmaceutical company Alkermes has entered into a settlement and licence agreement with generic maker Amneal Pharmaceuticals to resolve an inter partes review (IPR).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Alkermes, Amneal, opioid dependence, inter partes review, IPR, PTAB, settlement, generics, Vivitrol
